Search results for "Kidney Neoplasms"

showing 10 items of 207 documents

Chromosomal changes in renal oncocytomas Evidence that t(5;11)(q35;q13) may characterize a second subgroup of oncocytomas

1995

Many of the reported oncocytomas have different chromosome abnormalities, indicating that they comprise a cytogenetically heterogenous group of tumors consisting of potentially cytogenetic subgroups. We have performed cytogenetic studies on nine renal oncocytomas. Clonal abnormalities were present in eight tumors. The findings most observed were the loss of the Y chromosome, and abnormalities of chromosomes 1 and 22. We also observed telomeric associations (tas) in two tumors and structural aberrations of chromosomes 9p and 19q, as well as monosomy 10. In two cases we found a similar reciprocal t(5;11)(q35;q13) in two cases. Review of the literature disclosed one other oncocytoma with a t(5…

AdenomaMalecongenital hereditary and neonatal diseases and abnormalitiesCancer ResearchMonosomyPathologymedicine.medical_specialtyChromosomal translocationBiologyurologic and male genital diseasesY chromosomeTranslocation GeneticGeneticsmedicineHumansOncocytomaMolecular BiologyAgedChromosome AberrationsGeneticsChromosome 7 (human)KidneyChromosomes Human Pair 11ChromosomeCancerMiddle Agedmedicine.diseaseKidney Neoplasmsmedicine.anatomical_structureKaryotypingChromosomes Human Pair 5FemaleCancer Genetics and Cytogenetics
researchProduct

Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

1999

Hereditary papillary renal carcinoma (HPRC) is characterized by multiple, bilateral papillary renal carcinomas. Previously, we demonstrated missense mutations in the tyrosine kinase domain of the MET proto-oncogene in HPRC and a subset of sporadic papillary renal carcinomas. In this study, we screened a large panel of sporadic papillary renal carcinomas and various solid tumors for mutations in the MET proto-oncogene. Summarizing these and previous results, mutations of the MET proto-oncogene were detected in 17/129 sporadic papillary renal carcinomas but not in other solid tumors. We detected five novel missense mutations; three of five mutations were located in the ATP-binding region of t…

AdenomaModels MolecularCancer ResearchProtein ConformationDNA Mutational AnalysisMolecular Sequence DataHereditary Papillary Renal Cell CarcinomaBiologymedicine.disease_causeTransfectionProto-Oncogene MasReceptor tyrosine kinaseMiceAdenosine TriphosphateNeoplastic Syndromes HereditaryProto-OncogenesGeneticsCarcinomamedicineMissense mutationAnimalsHumansPoint MutationAmino Acid SequencePhosphorylationCodonMolecular BiologyKidneyMutationBinding SitesSequence Homology Amino AcidPoint mutation3T3 CellsDNA NeoplasmProto-Oncogene Proteins c-metmedicine.diseaseCarcinoma PapillaryKidney NeoplasmsNeoplasm Proteinsmedicine.anatomical_structureCell Transformation NeoplasticCancer researchbiology.proteinMutagenesis Site-DirectedTyrosine kinaseProtein Processing Post-TranslationalSequence AlignmentOncogene
researchProduct

Immunoperoxidase Staining of Fine-Needle Aspiration Biopsies of Renal Cell Carcinoma Using Tumor-Specific Monoclonal Antibody

1987

In 30 nephrectomy specimens, fine needle aspiration biopsies (FNAB) were performed both in the tumor and in the macroscopically normal part of the kidney: 18 were well differentiated renal cell carcinoma (RCC), 6 were moderately differentiated RCC, 4 were poorly differentiated RCC, and 2 were oncocytomas. FNAB was also performed in a bone metastasis of RCC. FNAB materials were stained using the immunoperoxidase method with RCC-specific monoclonal antibody and were compared with the staining of frozen sections. In all cases where tumor-antigen expression could be demonstrated in the frozen sections, a FNAB had already proven positive. There were only 2 false-negative cases where sufficient c…

AdenomaPathologymedicine.medical_specialtymedicine.drug_classUrologymedicine.medical_treatmenturologic and male genital diseasesMonoclonal antibodyImmunoenzyme TechniquesAntigens NeoplasmRenal cell carcinomaBiopsymedicineHumansCarcinoma Renal CellFrozen section proceduremedicine.diagnostic_testImmunoperoxidasebusiness.industryBiopsy NeedleAntibodies Monoclonalmedicine.diseaseKidney Neoplasmsfemale genital diseases and pregnancy complicationsNephrectomyStainingFine-needle aspirationbusinessEuropean Urology
researchProduct

Primitive Neuroectodermal Tumor (PNET) of the kidney: a case report.

2004

Abstract Background A case of Primitive Neuroectodermal Tumor (PNET) of the kidney in a 27-year-old woman is presented. Few cases are reported in the literature with a variable, nonspecific presentation and an aggressive behaviour. In our case, a radical nephrectomy with lymphadenectomy was performed and there was no residual or recurrent tumour at 24-month follow-up. Methods The surgical specimens were formalin-fixed and paraffin embedded. The sections were stained with routinary H&E. Immunohistochemistry was performed. Results The immunohistochemical evaluation revealed a diffuse CD99 positivity in the cytoplasm of the neoplastic cells. Pankeratin, cytokeratin AE1/AE3, vimentin, desmin, S…

AdultEwing's SarcomaPNETCancer ResearchPathologymedicine.medical_specialtyRenal PNETmedicine.medical_treatmentCD99Case Reportlcsh:RC254-282Diagnosis DifferentialCytokeratinImmunophenotypingSurgical oncologystem cellsGeneticsmedicineHumansNeuroectodermal Tumors Primitive Peripheralrhabdomyosarcoma tumorbusiness.industryEwing's sarcomalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseNephrectomyKidney NeoplasmsOncologyPrimitive neuroectodermal tumorFemaleDifferential diagnosisbusinesscarcinogenesis
researchProduct

Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries

2016

AbstractWe aimed at investigating the distribution and risk of second primary cancers (SPCs) in multiple myeloma (MM) survivors in Germany and Sweden to provide etiological understanding of SPCs and insight into their incidence rates and recording practices. MM patients diagnosed in 1997–2010 at age ≥15 years were selected from the Swedish (nationwide) and 12 German cancer registries. Standardized incidence ratios (SIRs) were used to assess risk of a specific SPC compared to risk of the same first cancer in the corresponding background population. Among 18,735 survivors of first MM in Germany and 7,560 in Sweden, overall 752 and 349 SPCs were recorded, respectively. Significantly elevated S…

AdultMale0301 basic medicineOncologyPediatricsmedicine.medical_specialtyTime FactorsMyeloidAdolescentNervous System NeoplasmsPopulationAntineoplastic AgentsArticle03 medical and health sciences0302 clinical medicineRisk FactorsGermanyInternal medicinemedicineHumansRegistriesSurvivorseducationMultiple myelomaAgedSwedeneducation.field_of_studyMultidisciplinarybusiness.industryIncidence (epidemiology)CancerNeoplasms Second PrimaryMiddle Agedmedicine.diseaseKidney NeoplasmsLeukemia Myeloid AcuteLeukemiaEarly Diagnosis030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisEpidemiology ; Cancer epidemiology ; MyelomaEtiologyFemaleMultiple MyelomabusinessKidney cancerScientific Reports
researchProduct

Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results

2019

Abstract Background This multi-institutional retrospective real life study was conducted in 22 Italian Oncology Centers and evaluated the role of Axitinib in second line treatment in not selected mRCC patients. Methods 148 mRCC patients were evaluated. According to Heng score 15.5%, 60.1% and 24.4% of patients were at poor risk, intermediate and favorable risk, respectively. Results PFS, OS, DCR and ORR were 7.14 months, 15.5 months, 70.6% and 16.6%, respectively. The duration of prior sunitinib treatment correlated with a longer significant mPFS, 8.8 vs 6.3 months, respectively. Axitinib therapy was safe, without grade 4 adverse events. The most frequent toxicities of all grades were: fati…

AdultMale0301 basic medicineOncologymedicine.medical_specialtyMultivariate analysisAxitinibAxitinib; Metastatic; Renal cancer; Sunitinib; Treatmentmedicine.medical_treatmentPopulationlcsh:MedicineKaplan-Meier EstimateDisease-Free SurvivalGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineInternal medicineSunitinibHumansMedicineNeoplasm MetastasiseducationAdverse effectMetastatic renal cell cancerCarcinoma Renal CellAgedAged 80 and overSecond-line therapyeducation.field_of_studybusiness.industrySunitinibResearchlcsh:RGeneral MedicineMiddle AgedKidney NeoplasmsNephrectomyAxitinibTreatment030104 developmental biologyRenal cancer030220 oncology & carcinogenesisMultivariate AnalysisMetastaticFemalebusinessmedicine.drugJournal of Translational Medicine
researchProduct

High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal c…

2018

Papillary renal cell carcinoma (PRCC) is currently divided in 2 subtypes. We reviewed a large cohort of PRCC and correlated subtype, morphological features and diagnostic marker expression with overall survival (OS) to uncover differences between the 2 subtypes. Three hundred seventy-six renal tumors initially diagnosed as PRCC with clinical and survival data were collected from the participating centers. Two hundred forty-six tumors were classified as PRCC1 (65.4%) and 130 as PRCC2 (34.6%) and graded according to the 2016 World Health Organization/International Society of Urological Pathology grading system. Morphological features (abundant cytoplasm, necrosis, fibrous stroma, foamy macrop…

AdultMale0301 basic medicinemedicine.medical_specialtyPathologyAdolescentPsammoma bodyPathology and Forensic MedicineMetastasisYoung Adult03 medical and health sciences0302 clinical medicineRenal cell carcinomamedicineHumansStage (cooking)ChildCarcinoma Renal CellAgedCell ProliferationNeoplasm StagingAged 80 and overTissue microarrayPapillary renal cell carcinomasbusiness.industryMiddle AgedPrognosismedicine.diseaseKidney Neoplasms030104 developmental biology030220 oncology & carcinogenesisImmunohistochemistryFemaleHistopathologybusinessHuman Pathology
researchProduct

Predictive chromosomal clusters of synchronous and metachronous brain metastases in clear cell renal cell carcinoma

2014

Synchronous (early) and metachronous (late) brain metastasis (BM) events of sporadic clear cell renal cell carcinoma (ccRCC) (n = 148) were retrospectively analyzed using comparative genomic hybridization (CGH). Using oncogenetic tree models and cluster analyses, chromosomal imbalances related to recurrence-free survival until BM (RFS-BM) were analyzed. Losses at 9p and 9q appeared to be hallmarks of metachronous BM events, whereas an absence of detectable chromosomal changes at 3p was often associated with synchronous BM events. Correspondingly, k-means clustering showed that cluster 1 cases generally exhibited low copy number chromosomal changes that did not involve 3p. Cluster 2 cases ha…

AdultMaleCancer ResearchDNA Copy Number VariationsMedizinChromosome 9BiologySporadic Clear Cell Renal Cell Carcinoma03 medical and health sciences0302 clinical medicineGeneticsmedicineHumansCarcinoma Renal CellMolecular BiologyAgedRetrospective StudiesSequence Deletion030304 developmental biologyAged 80 and overChromosome AberrationsGeneticsComparative Genomic Hybridization0303 health sciencesBase SequenceBrain NeoplasmsChromosomeDNA NeoplasmMiddle Agedmedicine.diseaseKidney NeoplasmsClear cell renal cell carcinomaTumor progression030220 oncology & carcinogenesisCancer researchFemaleNeoplasm Recurrence LocalLow copy numberComparative genomic hybridizationBrain metastasisCancer Genetics
researchProduct

Migration of renal tumor cells depends on dephosphorylation of Shc by PTEN.

2011

The tumor suppressor PTEN is a phosphatase using FAK and Shc as direct substrates, and Akt as a key effector via PIP3. PTEN regulates cell migration and may influence metastases. We quantified PTEN in 135 clear cell renal cell carcinomas (ccRCC) by Western blot analysis and found statistically significant lower PTEN expression in patients who died, usually caused by metastases, within 5 years after surgery, compared to those surviving this time period. In athymic mice, PTEN transfected 786-O cells were injected into the tail vein and metastatic load of the lungs was quantified. We observed a strongly reduced metastatic load after PTEN transfection. For analyses of the PTEN activities, trans…

AdultMaleCancer ResearchSrc Homology 2 Domain-Containing Transforming Protein 1PhosphataseTransplantation HeterologousMice NudeBiologyMiceCell MovementTumor Cells CulturedPTENAnimalsHumansNeoplasm MetastasisPhosphorylationProtein kinase BCarcinoma Renal CellAgedAged 80 and overOncogenePTEN PhosphohydrolaseCell migrationCell cycleMiddle AgedPrognosisSurvival AnalysisKidney NeoplasmsGene Expression Regulation NeoplasticOncologyShc Signaling Adaptor ProteinsLipid phosphatase activityCancer researchbiology.proteinPhosphorylationFemaleInternational journal of oncology
researchProduct

Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma--a multicentre study.

2012

Abstract Aim of the study Papillary renal cell carcinoma (pRCC) is the second most common subtype of RCC after the conventional clear cell type (cRCC). However, its characteristics and prognosis have been less intensively investigated. The aim of our study was to examine the tumour characteristics and long-term prognosis of pRCC compared to clear cell RCC (cRCC). Methods In total, 4941 evaluable patients were subjected to either radical nephrectomy or nephron-sparing surgery for pRCC or cRCC at five centres in Germany (University Hospitals of Hannover, Homburg/Saar, Mainz, Ulm and Marburg) between 1990 and 2010. Results pRCC ( n  = 565) and cRCC ( n  = 4376) patients were comparable with re…

AdultMaleCancer Researchmedicine.medical_specialtyPathologymedicine.medical_treatmentGastroenterologyYoung AdultInternal medicineGermanyCarcinomaMedicineHumansSurvival rateCarcinoma Renal CellAgedRetrospective StudiesAged 80 and overPapillary renal cell carcinomasbusiness.industryIncidenceMiddle Agedmedicine.diseasePrognosisNephrectomyKidney NeoplasmsSurvival RateClear cell renal cell carcinomaOncologyClear cell carcinomaFemalebusinessKidney cancerClear cellEuropean journal of cancer (Oxford, England : 1990)
researchProduct